Senior Scientist and Director NIH/NCI/CCR Comparative Oncology Program Bethesda, Maryland, United States
Background Key gaps in knowledge persist in the translatability of canine osteosarcoma (OS) to its human counterpart, inclusive of histologic, genomic and transcriptomic features. Under the NCI’s Decoding the Osteosarcoma Genome of the Dog (DOG2) project, we are addressing these gaps through a multi-omic approach.
Hypothesis/Objectives To leverage the DOG2 outcome-linked OS biorepository to 1. identify prognostic signatures for canine OS that could be translated to human patients and 2. to identify new druggable targets that can be biologically and experimentally validated.
Animals 324 dogs with osteosarcoma were enrolled in 2 NCI-COTC clinical trials, resulting in over 22,000 outcome-linked samples. A sample/data archive was created using LabMatrix to organize and track samples, images, and accompanying clinical and genomic/transcriptomic datasets.
Methods We have completed pathology review and nucleic isolation from primary OS tumors, normal tissues and metastatic samples. Analytical platforms include bulk and single-nuclei RNAseq, whole genome sequencing, whole exome sequencing, methylation profiling, multiplex IHC and Nanostring IO profiling.
Results See Table for a summary of sample numbers and analysis platforms.
Conclusions and clinical importance The DOG2 biospecimen repository is enabling the creation of a clinical, genomic, and pathologic framework for canine OS, which will further enhance the translational value of the pet dog as a naturally-occurring animal model for humans.
.jpg "Amy K. LeBlanc, DVM, DACVIM(O) photo")
